Drawing for LIFESEQ

USPTO serial 85891977

LIFESEQ

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
NELSON, EDWARD
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with LIFESEQ?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michelle L. Mehok

MICHELLE L. MEHOK PILLSBURY WINTHROP SHAW PITTMAN, LLP12255 EL CAMINO REAL STE 300SAN DIEGO, CA 92130-4088UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
009Computer software programs for analyzing, storing, querying and computing biological sequence data, for use in the fields of bioinformatics and biotechnologiesACTIVE—
042Genomic and bioinformatics testing, namely, genetic testing for medical research and scientific research purposes; providing medical research and scientific research information in the field of molecular genetics; consulting services in the field of genomics and biological sequence processing and analysis for scientific research and medical research purposes; development of new technology for others in the field of molecular genetics; DNA analysis and screening for scientific research purposes; compiling data for research purposes in the field of medical science and medical consultancy; DNA analysis services; DNA screening for scientific research purposes; genetic mapping for scientific purposes; Providing information in the field of disease classificationACTIVE—
044Diagnostic services in the field of medicine; medical testing for diagnosis of diseases; genomic and bioinformatics testing, namely, genetic testing for medical diagnostic and treatment purposes; DNA screening for medical diagnostic and treatment purposes; DNA analysis and screening for medical diagnostic and treatment purposes; DNA screening for medical purposes; consulting services in the field of genomics and biological sequence processing and analysis for medical diagnosis and treatment purposes; providing medical information for the purposes of medical diagnosis and treatment in the field of molecular geneticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Nov 23, 2015MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 23, 2015ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Apr 21, 2015EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 20, 2015EX3GSOU EXTENSION 3 GRANTED—
Apr 16, 2015EXT3SOU EXTENSION 3 FILED—
Apr 16, 2015EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 25, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Oct 24, 2014EX2GSOU EXTENSION 2 GRANTED—
Oct 20, 2014EXT2SOU EXTENSION 2 FILED—
Oct 20, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 12, 2014NOACCORRECTED NOA E-MAILED—
Jul 11, 2014ICNANOTICE OF ALLOWANCE CORRECTION ENTERED—
Jul 11, 2014AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 18, 2014EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Apr 19, 2014EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Apr 17, 2014EX1GSOU EXTENSION 1 GRANTED—
Apr 17, 2014EXT1SOU EXTENSION 1 FILED—
Apr 17, 2014EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 22, 2013NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Aug 27, 2013NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Aug 27, 2013PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Aug 7, 2013NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jul 16, 2013CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 15, 2013DOCKASSIGNED TO EXAMINER—
Apr 9, 2013MPMKNOTICE OF PSEUDO MARK E-MAILED—
Apr 6, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 4, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance